triazulenone has been researched along with Sleep-Wake-Disorders* in 5 studies
1 review(s) available for triazulenone and Sleep-Wake-Disorders
Article | Year |
---|---|
Loprazolam: an intermediate acting benzodiazepine. A review article.
Topics: Adult; Aged; Animals; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Brain; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Ethanol; Female; Humans; Psychomotor Performance; Sleep; Sleep Wake Disorders | 1983 |
4 trial(s) available for triazulenone and Sleep-Wake-Disorders
Article | Year |
---|---|
Clinical and psychometric evaluation of two doses of loprazolam and placebo in geriatric patients.
A double-blind, parallel group, randomized trial was carried out to compare the hypnotic efficacy, tolerance and psychometric effects of two doses of loprazolam and placebo in 89 elderly hospital in-patients. All had disturbed sleep patterns, which were not the result of serious psychiatric or physical illness and, after a 1 or 2 day single-blind placebo baseline period, they received either 0.5 mg or 1.0 mg loprazolam or placebo administered double-blind for 5 days. The sleep of patients in all three treatment groups, as measured by patient self-rating scales, substantially improved during the study, with loprazolam being superior to placebo for measures of sleep latency, satisfaction with sleep, number of nocturnal awakenings and feeling refreshed on waking. Differences in hypnotic efficacy between the 0.5 mg and 1.0 mg loprazolam groups were not significant. The incidence of side-effects was low and, although there was a significant relationship with loprazolam treatment, this was not dose-related. Performance tests for residual effects (critical flicker fusion threshold and choice reaction time) showed no difference between the placebo and active treatment groups, suggesting that loprazolam, even in a dose of 1.0 mg, is unlikely to produce hangover effects. It is concluded that the findings confirm that loprazolam is an effective and well-tolerated hypnotic in the elderly and that a 0.5 mg dose would be an appropriate initial dose for older patients. Topics: Aged; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Choice Behavior; Double-Blind Method; Drug Evaluation; Female; Flicker Fusion; Humans; Hypnotics and Sedatives; Male; Patient Dropouts; Placebos; Random Allocation; Reaction Time; Sleep Wake Disorders | 1986 |
A comparison of the hypnotic activity of loprazolam, flurazepam and placebo.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clinical Trials as Topic; Double-Blind Method; Female; Flurazepam; Humans; Male; Middle Aged; Sleep Wake Disorders | 1984 |
Effect of loprazolam and of triazolam on psychological functions.
Twelve poor sleepers of mean age 52 years performed 2 h of laboratory tests three times on 1 day during each week of nightly intake of loprazolam 0.5 mg, loprazolam 1 mg, triazolam 0.5 mg, or continued placebos. Only in the mornings did loprazolam 1 mg cause impairment in manual dexterity and card-sorting, and triazolam 0.5 mg in manual dexterity. Using difference from baseline, withdrawal of either drug after 3 weeks was associated with poorer subjective quality of sleep than following continuing placebos. The rate of spontaneous complaints (including accidents) associated with the drugs was as informative as formal testing. Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Female; Humans; Male; Middle Aged; Psychomotor Performance; Sleep Wake Disorders; Triazolam | 1984 |
Loprazolam: an intermediate acting benzodiazepine. A review article.
Topics: Adult; Aged; Animals; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Brain; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Ethanol; Female; Humans; Psychomotor Performance; Sleep; Sleep Wake Disorders | 1983 |
1 other study(ies) available for triazulenone and Sleep-Wake-Disorders
Article | Year |
---|---|
Effects of loprazolam and of triazolam on sleep and overnight urinary cortisol.
Nine poor sleepers of mean age 61 years were studied while they took loprazolam 0.5 mg, loprazolam 1 mg and triazolam 0.5 mg for 3-week periods. Loprazolam 1 mg and triazolam 0.5 mg increased sleep duration, but there was some tolerance to both, particularly triazolam, by the 3rd week. Withdrawal of either drug led to sleep significantly shorter than baseline. This rebound effect was significant greater than withdrawing triazolam. After withdrawing loprazolam 1 mg, the rebound was maximal on the 3rd night and after withdrawing triazolam it was maximal and severe on the 1st night. In the third week of use neither drug was associated with late-night wakefulness. Total overnight urinary cortisol was lower during drug intake and there were significant withdrawal rebounds to above baseline levels, immediately so after triazolam. Topics: Aged; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Catecholamines; Drug Tolerance; Female; Humans; Hydrocortisone; Male; Middle Aged; Sleep; Sleep Wake Disorders; Substance Withdrawal Syndrome; Time Factors; Triazolam | 1984 |